ClinicalTrials.gg
CompletedNCT04939428MOVe-AHEADUpdated Sep 26, 2024Results posted

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

A Phase 3 interventional study of Molnupiravir and Placebo in Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme LLC. Completed at 226 sites in 23 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,441
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.

Enrollment
4th of 14
2,441 · median 275
Started
2021
with 3 others
Phase 3
5 of 14
2 open now
Registered
7th of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing molnupiravir in COVID-19, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 7th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About molnupiravir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing molnupiravir in COVID-19, or all of them as a file.
02

Study summary

The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.

03

Conditions studied

  • Coronavirus Disease (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lives in a household with an index case where the index case is a person with documented COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms case) and must have 1) a first detectable SARS-CoV-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to COVID-19 (e.g., fever, difficulty breathing)
  • Does not have confirmed or suspected COVID-19
  • Is willing and able to take oral medication
  • For males, agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective method while receiving study drug and for ≥3 months after the last dose of study drug
  • Is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of (WOCBP), is a WOCBP and uses highly effective contraception (low user dependency method OR a user dependent hormonal method in combination with a barrier method), or is a WOCBP who is abstinent from heterosexual intercourse

Exclusion criteria

Exclusion Criteria:

  • Has a prior history of laboratory-confirmed SARS-CoV-2 infection (with or without symptoms) within 6 months prior to randomization
  • Has either of the following: (HIV) with a recent viral load >50 copies/mL (regardless of ) or an acquired immunodeficiency syndrome (AIDS)-defining illness
  • Has a history of virus (HBV) or virus (HCV) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; (AST) and/or (ALT) >3x at screening
  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents
  • Has received, is taking, or is anticipated to require any prohibited therapies
  • Has received a COVID-19 vaccination with the first dose ≥7 days prior to randomization
  • Is unwilling to abstain from participating in another interventional clinical study through Day 29 with an compound or device, including those for COVID-19 therapeutics
  • Is living in a household with >10 people
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,441 participants (actual)

Study arms

  • Experimental
    Molnupiravir

    Participants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.

    Drug: Molnupiravir

  • Placebo comparator
    Placebo

    Participants take placebo Q12H on Days 1 to 5.

    Drug: Placebo

Interventions

  • Four molnupiravir 200 mg capsules taken by mouth.

    Also known as: MK-4482

  • DrugPlacebo

    Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14

    Percentage of participants who had undetectable SARS-CoV-2 in baseline NP swabs and developed COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 were reported.

    Time frame: Day 14

  2. Percentage of Participants With ≥1 Adverse Event

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: 29 days

  3. Percentage of Participants Discontinuing From Study Therapy Due to AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 5 days

Secondary outcomes

  1. Percentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14

    Participants who experienced targeted symptoms of COVID-19 (e.g., cough, sore throat) and had NP swabs tested for SARS-CoV-2 using reverse-transcription polymerase chain reaction (RT-PCR).Efficacy analysis was conducted on the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

    Time frame: Up to Day 14

  2. Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 29

    Participants who experienced targeted symptoms of COVID-19 (e.g., cough, sore throat) and had NP swabs tested for SARS-CoV-2 using RT-PCR. The efficacy analysis population was the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

    Time frame: Up to Day 29

  3. Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed Detectable SARS-CoV-2 in NP Swabs on or Before Day 14

    All participants had NP swabs collected at screening and through Day 14 to test for SARS-CoV-2 using RT-PCR. Efficacy analysis was conducted on the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

    Time frame: Up to Day 14

  4. Percentage of Participants Who Had Detectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14

    Participants who experienced targeted symptoms of COVID-19 (e.g., cough, sore throat) and had NP swabs tested for SARS-CoV-2 using RT-PCR. Efficacy analysis was conducted on the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

    Time frame: Up to Day 14

07

Results

Posted Feb 6, 2024

Participant flow

Only eligible participants without confirmed or suspected coronavirus disease 2019 (COVID-19) were enrolled within a 5-day period of the index case's first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result and COVID-19 symptoms onset.

Participant flow — Overall Study
MilestoneMolnupiravirPlaceboIndex Participants
Started768771902
Treated7637650
Completed7507510
Not completed1820902
Withdrew: Death010
Withdrew: Lost to follow-up050
Withdrew: Physician decision100
Withdrew: Randomized by mistake without study treatment100
Withdrew: Withdrawal by subject10110
Withdrew: Unkown630
Withdrew: Discotinued per protocol00902

Outcome measures

PrimaryPercentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14

Percentage of participants who had undetectable SARS-CoV-2 in baseline NP swabs and developed COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 were reported.

Time frame:
Day 14
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
Percentage of ParticipantsMolnupiravirPlacebo
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 144154
Statistical analysis
  • Molnupiravir vs Placebo · Miettinen & Nurminen method · p = = 0.0848 · Confidence interval: -2 · 95% CI -5 to 0.9
PrimaryPercentage of Participants With ≥1 Adverse Event

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
29 days
Reported as:
Count of participants · Participants
Percentage of Participants With ≥1 Adverse Event
ParticipantsMolnupiravirPlacebo
Percentage of Participants With ≥1 Adverse Event94105
Statistical analysis
  • Molnupiravir vs Placebo · Miettinen & Nurminen method · Confidence interval: -1.4 · 95% CI -4.8 to 2.0
PrimaryPercentage of Participants Discontinuing From Study Therapy Due to AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 5 days
Reported as:
Count of participants · Participants
Percentage of Participants Discontinuing From Study Therapy Due to AE
ParticipantsMolnupiravirPlacebo
Percentage of Participants Discontinuing From Study Therapy Due to AE31
Statistical analysis
  • Molnupiravir vs Placebo · Miettinen & Nurminen method. · Confidence interval: 0.3 · 95% CI -0.4 to 1.0
SecondaryPercentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14

Participants who experienced targeted symptoms of COVID-19 (e.g., cough, sore throat) and had NP swabs tested for SARS-CoV-2 using reverse-transcription polymerase chain reaction (RT-PCR).Efficacy analysis was conducted on the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Percentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
ParticipantsMolnupiravirPlacebo
Percentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 1478103
Statistical analysis
  • Molnupiravir vs Placebo · Miettinen & Nurminen method · p = = 0.0205 · Confidence interval: -3.2 · 95% CI -6.3 to -0.1
SecondaryPercentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 29

Participants who experienced targeted symptoms of COVID-19 (e.g., cough, sore throat) and had NP swabs tested for SARS-CoV-2 using RT-PCR. The efficacy analysis population was the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 29
ParticipantsMolnupiravirPlacebo
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 295165
Statistical analysis
  • Molnupiravir vs Placebo · Miettinen & Nurminen method · Confidence interval: -2.2 · 95% CI -5.4 to 1.0
SecondaryPercentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed Detectable SARS-CoV-2 in NP Swabs on or Before Day 14

All participants had NP swabs collected at screening and through Day 14 to test for SARS-CoV-2 using RT-PCR. Efficacy analysis was conducted on the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed Detectable SARS-CoV-2 in NP Swabs on or Before Day 14
ParticipantsMolnupiravirPlacebo
Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline NP Swabs and Developed Detectable SARS-CoV-2 in NP Swabs on or Before Day 146585
Statistical analysis
  • Molnupiravir vs Placebo · Confidence interval: -3 · 95% CI -6.9 to 0.8
SecondaryPercentage of Participants Who Had Detectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14

Participants who experienced targeted symptoms of COVID-19 (e.g., cough, sore throat) and had NP swabs tested for SARS-CoV-2 using RT-PCR. Efficacy analysis was conducted on the mITT (modified intent to treat) population consisting of all randomized participants who received at least 1 dose of study intervention.

Time frame:
Up to Day 14
Reported as:
Count of participants · Participants
Percentage of Participants Who Had Detectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14
ParticipantsMolnupiravirPlacebo
Percentage of Participants Who Had Detectable SARS-CoV-2 in Baseline NP Swabs and Developed COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) Through Day 143547
Statistical analysis
  • Molnupiravir vs Placebo · Miettinen & Nurminen method · Mean difference (final values): -10.5 · 95% CI -22.7 to 2.0

Adverse events

Collected over Up to Day 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-44820/768 (0%)3/763 (0.4%)0/763 (0%)
Placebo1/771 (0.1%)2/765 (0.3%)0/765 (0%)
Most frequent serious events
Most frequent serious events
EventMK-4482Placebo
COVID-19 pneumoniaInfections and infestations2/7631/765
Femur fractureInjury, poisoning and procedural complications1/7630/765
Acute myocardial infarctionCardiac disorders0/7631/765

Baseline characteristics

Age, Continuous
Age, Continuous(years)MolnupiravirPlaceboIndex ParticipantsTotal
Median37.0 ± 15.637.0 ± 15.538.0 ± 17.737.0 ± 15.6
Age, Customized
Age, Customized(Participants)MolnupiravirPlaceboIndex ParticipantsTotal
<18007676
Adults (18-49 years)5635685481679
From 50 to 64 years144141199484
From 65 to 74 years354454133
>=75 years26182569
Sex: Female, Male
Sex: Female, Male(Participants)MolnupiravirPlaceboIndex ParticipantsTotal
Female3663425411249
Male4024293611192
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MolnupiravirPlaceboIndex ParticipantsTotal
Hispanic or Latino3233403411004
Not Hispanic or Latino4454305521427
Unknown or Not Reported01910
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MolnupiravirPlaceboIndex ParticipantsTotal
American Indian or Alaska Native859080255
Asian484062150
Native Hawaiian or Other Pacific Islander1427
Black or African American626077199
White4534465521451
More than one race119129128376
Unknown or Not Reported0213
Stratification Factor at Randomization Collected via IRT: Household Size
Stratification Factor at Randomization Collected via IRT: Household Size(Participants)MolnupiravirPlaceboIndex ParticipantsTotal
<=32692710540
>=34995000999
Stratification Factor at Randomization Collected via IRT: Age Group
Stratification Factor at Randomization Collected via IRT: Age Group(Participants)MolnupiravirPlaceboIndex ParticipantsTotal
<=6068068001360
>=6088910179
08

Study locations

226 sites
  • Cahaba Research, Inc. ( Site 2523)
    Birmingham, Alabama 35235, United States
  • The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2484)
    Mesa, Arizona 85210, United States
  • The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2448)
    Tucson, Arizona 85712, United States
  • Hope Clinical Research ( Site 2400)
    Canoga Park, California 91303, United States
  • Carbon Health ( Site 2515)
    Carlsbad, California 92009, United States
  • UCSF Fresno ( Site 2528)
    Fresno, California 93701, United States
  • ASCADA Research, LLC ( Site 2516)
    Fullerton, California 92835, United States
  • Marvel Clinical Research ( Site 2490)
    Huntington Beach, California 92647, United States
  • National Research Institute ( Site 2452)
    Los Angeles, California 90057, United States
  • Valley Clinical Trials Inc. ( Site 2406)
    Northridge, California 91325, United States
  • Carbon Health ( Site 2514)
    Oakland, California 94610, United States
  • University of California Davis ( Site 2497)
    Sacramento, California 95817, United States
  • Millennium Clinical Trials ( Site 2468)
    Simi Valley, California 93065, United States
  • Future Innovative Treatments, LLC ( Site 2471)
    Colorado Springs, Colorado 80907, United States
  • Emerson Clinical Research Institute ( Site 2457)
    Washington, District of Columbia 20011, United States
  • Synergy Healthcare ( Site 2521)
    Bradenton, Florida 34208, United States
  • Accel Research Sites-DeLand Clinical Research Unit ( Site 2535)
    DeLand, Florida 32720, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 2485)
    Hallandale Beach, Florida 33009, United States
  • Indago Research and Health Center Inc ( Site 2412)
    Hialeah, Florida 33012, United States
  • Advanced Research For Health Improvement LLC ( Site 2436)
    Immokalee, Florida 34142, United States
  • Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2508)
    Miami, Florida 33186, United States
  • CDC Research Institute, LLC ( Site 2540)
    Port Saint Lucie, Florida 34952, United States
  • Clinical Research Trials of Florida ( Site 2402)
    Tampa, Florida 33607, United States
  • Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2425)
    Winter Park, Florida 32789, United States
  • Balanced Life Healthcare Solutions/SKYCRNG ( Site 2539)
    Lawrenceville, Georgia 30046, United States
  • Chicago Clinical Research Institute Inc ( Site 2454)
    Chicago, Illinois 60607, United States
  • Rush University Medical Center ( Site 2510)
    Chicago, Illinois 60612, United States
  • Southern Clinical Research Associates ( Site 2542)
    Metairie, Louisiana 70001, United States
  • MedPharmics, LLC ( Site 2443)
    Metairie, Louisiana 70006, United States
  • Institute of Human Virology ( Site 2504)
    Baltimore, Maryland 21201, United States
  • Centennial Medical Group ( Site 2435)
    Elkridge, Maryland 21075, United States
  • Jadestone Clinical Research, LLC ( Site 2530)
    Silver Spring, Maryland 20904, United States
  • Michigan Center of Medical Research ( Site 2445)
    Farmington Hills, Michigan 48334, United States
  • Michigan Center of Medical Research ( Site 2525)
    Lathrup Village, Michigan 48076, United States
  • Allina Health Infectious Diseases Research Clinic ( Site 2507)
    Minneapolis, Minnesota 55404, United States
  • Prime Health and Wellness/SKYCRNG ( Site 2538)
    Fayette, Mississippi 39069, United States
  • Quinn Healthcare/Skycrng ( Site 2537)
    Ridgeland, Mississippi 39157, United States
  • University of Missouri Hospital ( Site 2486)
    Columbia, Missouri 65201, United States
  • Mercury Street Medical Group PLLC ( Site 2476)
    Butte, Montana 59701, United States
  • University of Nebraska Medical Center ( Site 2430)
    Omaha, Nebraska 68198-3135, United States
  • Excel Clinical Research, LLC ( Site 2404)
    Las Vegas, Nevada 89109, United States
  • ID Care ( Site 2466)
    Hillsborough, New Jersey 08844, United States
  • Amici Clinical Research LLC ( Site 2426)
    Raritan, New Jersey 08869, United States
  • AXCES Research Group ( Site 2437)
    Santa Fe, New Mexico 87505, United States
  • Montefiore Medical Center ( Site 2503)
    Bronx, New York 10462, United States
  • ECU Adult Specialty Care ( Site 2415)
    Greenville, North Carolina 27834, United States
  • The Lindner Center for Research and Education at The Christ Hospital ( Site 2517)
    Cincinnati, Ohio 45219, United States
  • Dayton Clinical Research ( Site 2488)
    Dayton, Ohio 45406, United States
  • Cherokee Nation WW Hastings Indian Hospital/Cherokee Nation Health Services ( Site 2459)
    Tahlequah, Oklahoma 74464, United States
  • Preferred Clinical Research ( Site 2470)
    Pittsburgh, Pennsylvania 15236, United States
  • Velocity Clinical Research-Providence ( Site 2432)
    East Greenwich, Rhode Island 02818, United States
  • Tribe Clinical Research, LLC ( Site 2409)
    Greenville, South Carolina 29607, United States
  • PharmaTex Research, LLC ( Site 2541)
    Amarillo, Texas 79109, United States
  • TTS Research ( Site 2433)
    Boerne, Texas 78006, United States
  • Houston Methodist Hospital ( Site 2463)
    Houston, Texas 77030, United States
  • Santa Clara Family Clinic ( Site 2462)
    Houston, Texas 77087, United States
  • Crossroads Clinical Research LLC ( Site 2451)
    Victoria, Texas 77901, United States
  • TPMG Clinical Research ( Site 2495)
    Williamsburg, Virginia 23188, United States
  • Covid-19 Clinical Research Center (CCRC) ( Site 2421)
    Seattle, Washington 98109, United States
  • Sanatorio de la Trinidad Mitre ( Site 0108)
    Caba, Buenos Aires C1039AAO, Argentina
  • Mautalen Salud e Investigacion ( Site 0103)
    Caba, Buenos Aires C1128AAF, Argentina
  • Hospital Italiano de Buenos Aires ( Site 0102)
    Caba, Buenos Aires C1199ABB, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0105)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • Clinica Independencia ( Site 0104)
    Munro, Buenos Aires B1605FRE, Argentina
  • Grupo Oroño Centro medico San Nicolas ( Site 0109)
    San Nicolas, Buenos Aires B2900DPA, Argentina
  • Instituto Medico de la Fundacion Estudios Clinicos ( Site 0106)
    Rosario, Santa Fe 2000, Argentina
  • CEMIC ( Site 0101)
    Buenos Aires, C1431FWO, Argentina
  • Fundaçao de Medicina Tropical Doutor Heitor Vieira Dourado ( Site 0303)
    Manaus, Amazonas 69040-000, Brazil
  • Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul - UFMS ( Site 0305)
    Campo Grande, Mato Grosso Do Sul 79070-900, Brazil
  • Hospital Nossa Senhora das Gracas ( Site 0310)
    Curitiba, Parana 80810-040, Brazil
  • Oncosite-Centro de Pesquisa Clinica em Oncologia ( Site 0300)
    Ijui, Rio Grande Do Sul 98700-000, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0312)
    São José do Rio Preto, Sao Paulo 15090000, Brazil
  • Centro de Referencia Professor Helio Fraga - FIOCRUZ/RJ ( Site 0314)
    Rio de Janeiro, 22780-192, Brazil
  • Centro de Referência e Treinamento DST/AIDS ( Site 0301)
    Sao Paulo, 04121-000, Brazil
  • Medical Center Hera EOOD ( Site 3001)
    Sofia, Sofia (stolitsa) 1510, Bulgaria
  • Medical Center Hera Kyustendi EOOD ( Site 3003)
    Kyustendil, 2500, Bulgaria
  • Medical Center Hera EOOD - Montana branch ( Site 3002)
    Montana, 3400, Bulgaria
  • Fundacion Centro de Investigacion Clinica CIC ( Site 0402)
    Medellin, Antioquia 050021, Colombia
  • Centro Cientifico Asistencial Jose Luis Accini ( Site 0412)
    Barranquilla, Atlantico 080020, Colombia
  • Clinica de la Costa Ltda. ( Site 0407)
    Barranquilla, Atlantico 080020, Colombia
  • Oncomedica S.A. ( Site 0406)
    Monteria, Cordoba 230002, Colombia
  • Hospital Universitario Clinica San Rafael ( Site 0410)
    Bogota, Cundinamarca 110411, Colombia
  • Healthy Medical Center S.A.S ( Site 0413)
    Zipaquira, Cundinamarca 250252, Colombia
  • Caja de Compensacion Familiar CAFAM ( Site 0403)
    Bogota, Distrito Capital De Bogota 111211, Colombia
  • Fundacion Centro de Investigaciones Clinicas CARDIOMET ( Site 0409)
    Pereira, Risaralda 660003, Colombia
  • Instituto Neumologico del Oriente S.A. ( Site 0408)
    Bucaramanga, Santander 681004, Colombia
  • Fundacion Valle del Lili ( Site 0405)
    Cali, Valle Del Cauca 760032, Colombia
  • Unidad de Aislamiento del Centro de Obstetricia y Ginecologia ( Site 2650)
    Santo Domingo, Distrito Nacional 10605, Dominican Republic
  • National Center for allergies and chest ( Site 2940)
    Giza, Al Jizah 12651, Egypt
  • Imbaba Fevers Hospital ( Site 2945)
    Giza, Al Jizah 12661, Egypt
  • Masri - CRC - Ain Shams University ( Site 2900)
    Cairo, Al Qahirah 11566, Egypt
  • Masri - CRC - Ain Shams University ( Site 2910)
    Cairo, Al Qahirah 11566, Egypt
  • National Hepatology and Tropical Medicine Research Institute ( Site 2930)
    Cairo, Al Qahirah 11796, Egypt
  • Air Force Specialized Hospital Clinical Research Center ( Site 2920)
    Cairo, Al Qahirah 11835, Egypt
  • Maison de Sante Universitaire La Providence ( Site 0506)
    Toulouse, Haute-Garonne 31500, France
  • Hôpital Pitié - Salpêtrière ( Site 0501)
    Paris, Ile-de-France 75013, France
  • CHU de la Reunion - Groupe Hospitalier Sud ( Site 0508)
    Saint Pierre Cedex, La Reunion 97448, France
  • CHU Martinique ( Site 0511)
    Fort-de-France, Martinique 97200, France
  • Maison de santé du Pays Neufchatelois ( Site 0507)
    Neufchatel-en-Bray, Seine-Maritime 76270, France
  • Centro de Investigaciones Pediatricas ( Site 0703)
    Guatemala, 01001, Guatemala

Showing the first 100 of 226 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Alpizar SA, Accini J, Anderson DC, Eysa B, Medina-Pinon I, Ohmagari N, Ostrovskyy MM, Aggrey-Amable A, Beck K, Byrne D, Grayson S, Hwang PMT, Lonchar JD, Strizki J, Xu Y, Paschke A, De Anda CS, Sears PS; MOVe-AHEAD study group. Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial. J Infect. 2023 Nov;87(5):392-402. doi: 10.1016/j.jinf.2023.08.016. Epub 2023 Sep 9. PubMed 37690669 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Nov 2022, 15 months.

Results were first posted in Feb 2024, 1 year 2 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 15 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jun 25, 2021
StartActual
Aug 11, 2021
Primary completionActual
Nov 16, 2022
CompletionActual
Nov 16, 2022
Results first posted
Feb 6, 2024
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04939428
Responsible party
Sponsor
First posted
Jun 25, 2021
Start date
Aug 11, 2021
Primary completion
Nov 16, 2022
Completion
Nov 16, 2022
Results posted
Feb 6, 2024
Last update
Sep 26, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion